stockrowRadNet, Inc.
RDNT Healthcare Diagnostics & Research
RadNet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 11.5% from fiscal 2024.
- Revenue
- +25.0%
- EPS
- −47.4%
- Free cash flow
- −43.2%
- Total debt
- +21.2%
Quarter to June 2026, against a year earlier
Follow RDNT
Alert me
RadNet, Inc. (RDNT) EV/FCF
As of 5 November 2026, RadNet, Inc. (RDNT) trades at a EV/FCF of 208×. Over the past ten years it has ranged from −654× (December 2022) to 1,829× (January 2025); the current reading is higher than 91% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 127× | (92.79%) |
| FY2024 | 1,760× | 47.09% |
| FY2023 | 1,196× | 1,917.06% |
| FY2022 | 59.3× | (67.97%) |
| FY2021 | 185× | 1,509.15% |
| FY2020 | 11.5× | (79.14%) |
| FY2019 | 55.2× | 135.13% |
| FY2018 | 23.5× | 93.91% |
| FY2017 | 12.1× | (55.02%) |
| FY2016 | 26.9× | (20.85%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 167× | 107.96% |
| Mar 2026 | 80.4× | (36.66%) |
| Dec 2025 | 127× | (78.94%) |
| Sep 2025 | 603× | 357.36% |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| ADPT Adaptive Biotechnologies Corporation compare | −494× |
| GRAL GRAIL, Inc. compare | −15.9× |
| VCYT Veracyte, Inc. compare | 9.0× |
| ICLR ICON PLC compare | 22.6× |
| QGEN QIAGEN N.V. compare | 25.8× |
| SHC Sotera Health Company compare | 47.0× |
| CDNA CareDx, Inc. compare | 64.7× |
| BLLN BillionToOne, Inc. compare | 142× |
| RDNT RadNet, Inc. | 208× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on RDNT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement